Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice - PubMed (original) (raw)
Comparative Study
Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice
Masaki Wakamatsu et al. Neurobiol Aging. 2008 Apr.
Abstract
Parkinson's disease is characterized by loss of nigral dopaminergic neurons and presence of Lewy bodies, whose major component is alpha-synuclein. In the present study, we generated transgenic mice termed Syn130m that express truncated human alpha-synuclein (amino acid residue number: 1-130) in dopaminergic neurons. Notably, dopaminergic neurons were selectively diminished in the substantia nigra pars compacta of Syn130m, while transgenic mice that expressed comparable amount of full-length human alpha-synuclein did not develop such pathology. Therefore, the truncation of human alpha-synuclein seems to be primarily responsible for the loss of nigral dopaminergic neurons. The nigral pathology resulted in impairment of axon terminals in the striatum and concomitant decrease in striatal dopamine content. Behaviorally, spontaneous locomotor activities of Syn130m were reduced, but the abnormality was ameliorated by treatment with L-DOPA. The loss of nigral dopaminergic neurons was not progressive and seemed to occur during embryogenesis along with the onset of expression of the transgene. Our results indicate that truncated human alpha-synuclein is deleterious to the development and/or survival of nigral dopaminergic neurons.
Similar articles
- Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
Wakamatsu M, Iwata S, Funakoshi T, Yoshimoto M. Wakamatsu M, et al. J Neurosci Res. 2008 Feb 15;86(3):640-6. doi: 10.1002/jnr.21513. J Neurosci Res. 2008. PMID: 17896793 - Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F, Lenzi P, Ferrucci M, Lazzeri G, di Poggio AB, Natale G, Busceti CL, Biagioni F, Giusiani M, Ruggieri S, Paparelli A. Fornai F, et al. Brain Res Bull. 2005 May 15;65(5):405-13. doi: 10.1016/j.brainresbull.2005.02.022. Brain Res Bull. 2005. PMID: 15833595 - Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter.
Matsuoka Y, Vila M, Lincoln S, McCormack A, Picciano M, LaFrancois J, Yu X, Dickson D, Langston WJ, McGowan E, Farrer M, Hardy J, Duff K, Przedborski S, Di Monte DA. Matsuoka Y, et al. Neurobiol Dis. 2001 Jun;8(3):535-9. doi: 10.1006/nbdi.2001.0392. Neurobiol Dis. 2001. PMID: 11442360 - Viral vectors, animal models and new therapies for Parkinson's disease.
Schneider B, Zufferey R, Aebischer P. Schneider B, et al. Parkinsonism Relat Disord. 2008;14 Suppl 2:S169-71. doi: 10.1016/j.parkreldis.2008.04.024. Epub 2008 Jun 27. Parkinsonism Relat Disord. 2008. PMID: 18585946 Review. - GABAergic control of substantia nigra dopaminergic neurons.
Tepper JM, Lee CR. Tepper JM, et al. Prog Brain Res. 2007;160:189-208. doi: 10.1016/S0079-6123(06)60011-3. Prog Brain Res. 2007. PMID: 17499115 Review.
Cited by
- Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.
Leão AH, Sarmento-Silva AJ, Santos JR, Ribeiro AM, Silva RH. Leão AH, et al. Brain Pathol. 2015 Jul;25(4):377-90. doi: 10.1111/bpa.12253. Epub 2015 Apr 22. Brain Pathol. 2015. PMID: 25726735 Free PMC article. Review. - Residue histidine 50 plays a key role in protecting α-synuclein from aggregation at physiological pH.
Chi YC, Armstrong GS, Jones DN, Eisenmesser EZ, Liu CW. Chi YC, et al. J Biol Chem. 2014 May 30;289(22):15474-81. doi: 10.1074/jbc.M113.544049. Epub 2014 Apr 17. J Biol Chem. 2014. PMID: 24742669 Free PMC article. - Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.
Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E. Games D, et al. Am J Pathol. 2013 Mar;182(3):940-53. doi: 10.1016/j.ajpath.2012.11.018. Epub 2013 Jan 9. Am J Pathol. 2013. PMID: 23313024 Free PMC article. - Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities.
Burré J, Sharma M, Südhof TC. Burré J, et al. J Neurosci. 2012 Oct 24;32(43):15227-42. doi: 10.1523/JNEUROSCI.3545-12.2012. J Neurosci. 2012. PMID: 23100443 Free PMC article. - Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α-synuclein.
Wang W, Nguyen LT, Burlak C, Chegini F, Guo F, Chataway T, Ju S, Fisher OS, Miller DW, Datta D, Wu F, Wu CX, Landeru A, Wells JA, Cookson MR, Boxer MB, Thomas CJ, Gai WP, Ringe D, Petsko GA, Hoang QQ. Wang W, et al. Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):9587-92. doi: 10.1073/pnas.1610099113. Epub 2016 Aug 1. Proc Natl Acad Sci U S A. 2016. PMID: 27482083 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous